<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816712</url>
  </required_header>
  <id_info>
    <org_study_id>0000-064</org_study_id>
    <secondary_id>2008_604</secondary_id>
    <nct_id>NCT00816712</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)</brief_title>
  <official_title>A Randomized, Single-Blind, Placebo-Controlled, Single-dose, Parallel Design Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (FSR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a study to evaluate the use of fractional synthetic rate as an early biomarker of
      muscle anabolism (muscle build-up).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thigh (vastus lateralis) muscle protein fractional synthetic rate one week after dosing with testosterone.</measure>
    <time_frame>One week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variability in the muscle fractional synthetic rate measurements.</measure>
    <time_frame>One week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Muscle Anabolism</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone - 300 mg IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone - 100 mg IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - IM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Testosterone 300 mg, intramuscular injection</intervention_name>
    <description>Day 1 &amp; 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 &amp; 7 - Testosterone 300 mg, Intramuscular injection.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Testosterone 100 mg, Intramuscular injection</intervention_name>
    <description>Day 1 &amp; 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 &amp; 7 - Testosterone 100 mg, Intramuscular injection.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo given by Intramuscular Injection</intervention_name>
    <description>Day 1 &amp; 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 &amp; 7 - Placebo given as intramuscular injection.</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is weight stable over the past 3 months

          -  Patient agrees to refrain from consumption of alcohol from 48 hours prior to entering
             the study

          -  Subject agrees to follow the study restriction of no caffeine while on study

          -  Patient agrees to following the meat-free controlled protein weight-maintaining diet

          -  Patient is willing to avoid strenuous physical activity

          -  Patient has been a nonsmoker for at least 6 months prior to study start

        Exclusion Criteria:

          -  Subject is currently a regular user of any illicit drugs

          -  Subject has taken androgenic steroids in the previous 12 months

          -  Subject has participated in sports events, resistance exercise training or heavy
             exercise in the previous month

          -  Subject has prostate cancer

          -  Subject has a history of cancer except basal-cell tumors

          -  Subject has been diagnosed with HIV

          -  Subject has been diagnosed with Hepatitis B or C

          -  Subject uses certain anti-inflammatory drugs such as ibuprofen, arcoxia or celecoxib

          -  Subject uses a blood anticoagulant, such as Coumadin (Warfarin) or high doses of
             aspirin

          -  Subject is currently taking over the counter supplements such as &quot;muscle builders&quot; or
             &quot;fat burners&quot;

          -  Subject has an allergy or hypersensitivity to intramuscular testosterone

          -  Subject has sciatica

          -  Subject has donated blood products or has had phlebotomy within 2 months of signing
             informed consent

          -  Subject has undergone a surgical procedure within 1 month of signing informed consent

          -  Subject is currently participating or has participated in a study with an
             investigational drug or device
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Chen F, Lam R, Shaywitz D, Hendrickson RC, Opiteck GJ, Wishengrad D, Liaw A, Song Q, Stewart AJ, Cummings CE, Beals C, Yarasheski KE, Reicin A, Ruddy M, Hu X, Yates NA, Menetski J, Herman GA. Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56. Epub 2011 Feb 26.</citation>
    <PMID>21475673</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2009</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Males with low-normal serum total testosterone levels.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

